Verastem (VSTM) Debt/Equity Ratio: History & Chart

Verastem, Inc.(VSTM)

Biotechnology · Needham, MA

$7.80-0.20 (-2.56%)

Delayed quote: Oct 6, 2026, 3:55 PM EDT

About Verastem, Inc.

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.

Needham, MA

102 employees

www.verastem.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel W. Paterson

View full financials

VSTM Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

1.69

DEBT TO EQUITY RATIO AVG TTM

0.17

DEBT TO EQUITY RATIO AVG 3Y

1.13

DEBT TO EQUITY RATIO AVG 5Y

0.71

DEBT TO EQUITY RATIO AVG 10Y

0.51

DEBT TO EQUITY RATIO AVG 15Y

0.25

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+900.87%

CURRENT VS 3Y AVG

+48.95%

CURRENT VS 5Y AVG

+139.26%

CURRENT VS 10Y AVG

+228.15%

CURRENT VS 15Y AVG

+569.86%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.11

median of 774 covered companies

CURRENT VS SECTOR MEDIAN

+1433.70%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Verastem, Inc. (VSTM)	$685.01M	1.69	0.17	1.13	0.71
Olema Pharmaceuticals, Inc. (OLMA)vs ›	$685.68M	0.00	0.00	0.01	0.01
Anteris Technologies Global Corp. (AVR)vs ›	$685.49M	0.01	0.06	0.15	0.44
Faeth Therapeutics, Inc. (FTH)vs ›	$692.72M	0.00	0.09	0.09	0.07
Wave Life Sciences Ltd. (WVE)vs ›	$690.65M	0.10	0.07	0.32	0.44
Solid Biosciences Inc. (SLDB)vs ›	$678.81M	0.05	0.15	0.16	0.12
ArriVent BioPharma, Inc. (AVBP)vs ›	$702.82M	0.00	0.00	0.00	0.00
Cytek Biosciences, Inc. (CTKB)vs ›	$694.79M	0.08	0.06	0.05	0.04
MiMedx Group, Inc. (MDXG)vs ›	$667.73M	0.01	0.11	0.32	0.40
Collegium Pharmaceutical, Inc. (COLL)vs ›	$709.65M	2.75	3.44	3.49	2.78

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Verastem, Inc. (VSTM)

$685.01M

1.69

0.17

1.13

0.71

Olema Pharmaceuticals, Inc. (OLMA)vs ›

$685.68M

0.00

0.01

Anteris Technologies Global Corp. (AVR)vs ›

$685.49M

0.01

0.06

0.15

0.44

Faeth Therapeutics, Inc. (FTH)vs ›

$692.72M

0.00

0.09

0.07

Wave Life Sciences Ltd. (WVE)vs ›

$690.65M

0.10

0.07

0.32

0.44

Solid Biosciences Inc. (SLDB)vs ›

$678.81M

0.05

0.15

0.16

0.12

ArriVent BioPharma, Inc. (AVBP)vs ›

$702.82M

0.00

Cytek Biosciences, Inc. (CTKB)vs ›

$694.79M

0.08

0.06

0.05

0.04

MiMedx Group, Inc. (MDXG)vs ›

$667.73M

0.01

0.11

0.32

0.40

Collegium Pharmaceutical, Inc. (COLL)vs ›

$709.65M

2.75

3.44

3.49

2.78

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Verastem, Inc. (VSTM)?

The debt to equity ratio for VSTM stock is 1.69.

Is Verastem, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 1.69 is 139% above its 5-year average of 0.71, near the high end of its 5-year range (-5.76–2.35).

What is the TTM average debt to equity ratio for Verastem, Inc. (VSTM)?

The TTM average debt to equity ratio for VSTM stock is 0.17.

What is the 3Y average debt to equity ratio for Verastem, Inc. (VSTM)?

The 3Y average debt to equity ratio for VSTM stock is 1.13.

What is the 5Y average debt to equity ratio for Verastem, Inc. (VSTM)?

The 5Y average debt to equity ratio for VSTM stock is 0.71.

What is the 10Y average debt to equity ratio for Verastem, Inc. (VSTM)?

The 10Y average debt to equity ratio for VSTM stock is 0.51.

What is the 15Y average debt to equity ratio for Verastem, Inc. (VSTM)?

The 15Y average debt to equity ratio for VSTM stock is 0.25.

DATE	DEBT TO EQUITY RATIO
2026-06-30	1.69
2026-03-31	1.05
2025-12-31	1.52
2025-09-30	-5.76
2025-06-30	2.35
2025-03-31	-2.37
2024-12-31	-1.46
2024-09-30	1.29
2024-06-30	1.05
2024-03-31	0.91
2023-12-31	0.72
2023-09-30	0.40
2023-06-30	0.35
2023-03-31	0.79
2022-12-31	0.57
2022-09-30	0.43
2022-06-30	0.50
2022-03-31	0.37
2021-12-31	0.04
2021-09-30	0.03
2021-06-30	0.27
2021-03-31	0.22
2020-12-31	0.20
2020-09-30	0.46
2020-06-30	0.52
2020-03-31	0.48
2019-12-31	14.99
2019-09-30	6.51
2019-06-30	2.80
2019-03-31	1.42
2018-12-31	0.97
2018-09-30	0.23
2018-06-30	0.20
2018-03-31	0.39
2017-12-31	0.26
2017-09-30	0.06
2017-06-30	0.05
2017-03-31	0.04
2016-12-31	0.00
2016-09-30	0.00
2016-06-30	0.00
2016-03-31	0.00
2015-12-31	0.00
2015-09-30	0.00
2015-06-30	0.00
2015-03-31	0.00
2014-12-31	0.00
2014-09-30	0.00
2014-06-30	0.00
2014-03-31	0.00
2013-12-31	0.00
2013-09-30	0.00
2013-06-30	0.00
2013-03-31	0.00
2012-12-31	0.00
2012-09-30	0.00
2012-06-30	0.00
2012-03-31	0.00
2011-12-31	0.00
2011-09-30	0.00
2011-06-30	0.00
2011-03-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

1.69

2026-03-31

1.05

2025-12-31

1.52

2025-09-30

-5.76

2025-06-30

2.35

2025-03-31

-2.37

2024-12-31

-1.46

2024-09-30

1.29

2024-06-30

1.05

2024-03-31

0.91

2023-12-31

0.72

2023-09-30

0.40

2023-06-30

0.35

2023-03-31

0.79

2022-12-31

0.57

2022-09-30

0.43

2022-06-30

0.50

2022-03-31

0.37

2021-12-31

0.04

2021-09-30

0.03

2021-06-30

0.27

2021-03-31

0.22

2020-12-31

0.20

2020-09-30

0.46

2020-06-30

0.52

2020-03-31

0.48

2019-12-31

14.99

2019-09-30

6.51

2019-06-30

2.80

2019-03-31

1.42

2018-12-31

0.97

2018-09-30

0.23

2018-06-30

0.20

2018-03-31

0.39

2017-12-31

0.26

2017-09-30

0.06

2017-06-30

0.05

2017-03-31

0.04

2016-12-31

0.00

2016-09-30

0.00

2016-06-30

0.00

2016-03-31

0.00

2015-12-31

0.00

2015-09-30

0.00

2015-06-30

0.00

2015-03-31

0.00

2014-12-31

0.00

2014-09-30

0.00

2014-06-30

0.00

2014-03-31

0.00

2013-12-31

0.00

2013-09-30

0.00

2013-06-30

0.00

2013-03-31

0.00

2012-12-31

0.00

2012-09-30

0.00

2012-06-30

0.00

2012-03-31

0.00

2011-12-31

0.00

2011-09-30

0.00

2011-06-30

0.00

2011-03-31

0.00

Debt to Equity Ratio: 1.69

VSTM Debt to Equity Ratio

VSTM Average Debt to Equity Ratio Chart

VSTM Current vs Average Debt to Equity Ratio Chart

VSTM Debt to Equity Ratio Metrics

VSTM Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

VSTM Debt to Equity Ratio History

Related Metrics